News|Articles|May 15, 2014
- Pharmaceutical Technology-05-15-2014
- Volume 2014 eBook
- Issue 2
Determining Cross-Contamination Risks in Multiproduct Biopharmaceutical Facilities
Author(s)Cynthia A. Challener
A global contract manufacturer of biologics discusses the increasing impact of health-based exposure limits in assessing cross-contamination risks.
Advertisement
A global contract manufacturer of biologics discusses the increasing impact of health-based exposure limits in assessing cross-contamination risks.
Download
.
Articles in this issue
about 12 years ago
Potential Benefits Drive Interest in Continuous Manufacturingabout 12 years ago
Continuous Bioprocessing Challengesabout 12 years ago
Achieving and Maintaining Compliance Using Continuous Monitoring Systemsabout 12 years ago
Optimizing the Sterilization of Liquids in Sealed Containersabout 12 years ago
Using Modular Systems in Biopharmaceutical Manufacturingabout 12 years ago
Determining Protein Oxidation Induced During Fill-Finish Operationsabout 12 years ago
Single-Use Technology in Parenteral Fill/FinishAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Ads, Alleging Omitted GLP-1 Dosing Data
2
What Jideytro's Approval Means for Drug Developers
3
Brent Wilhelm on Cold Chain Pharmaceuticals Reshaping Shipping Needs
4
Midyear 2026 Check in: Abzena’s Campbell Bunce on Trends in Antibody Drug Conjugates
5